Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña






Consumer News Weight Loss Drugs May Come With Serious Digestive Risks

Search Related Content

Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Consumer News Weight Loss Drugs May Come With Serious Digestive Risks is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.
Search RobinsPost News & Noticias


Consumer News Weight Loss Drugs May Come With Serious Digestive Risks | RobinsPost News & Noticias

A New Study Found That Weight-Loss Drugs Like Ozempic Could Lower Your Heart Attack Risk


Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular events. Read More

Endocrinologist explains dark side of weight loss drugs: Potential risks and benefits of Ozempic, Mounjaro, Wegovy


While Ozempic has dominated the weight loss space, Wegovy and Mounjaro are other injectable prescription weight loss drugs worth knowing about. But can these weight loss injections actually help ... Read More

Dangerous 'gray-market' weight-loss drugs flooding US as experts warn of risks


As demand for GLP-1 medications continues to skyrocket for weight loss and diabetes, more Americans are skipping pharmacies and turning to unregulated sellers as a way to avoid high prices, insurance ... Read More

Costco is offering discounts on weight loss drugs, but doctors are warning people about risks


CINCINNATI — Weight loss drugs like Ozempic and Wegovy just became significantly more affordable, with savings of nearly $1,000 per month available at Costco. But doctors say there's an important ... Read More

Novo Nordisk fights to keep Medicaid paying for weight-loss drugs


Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs. Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus